Expression patterns of BCL-6, MUM1, and CD138/syn-1 throughout the pathologic spectrum of HIV-related lymphomas
| . | Phenotypic patterns5-150 . | |||
|---|---|---|---|---|
| BCL6+/ MUM1−/ syn-1− . | BCL6−/ MUM1+/ syn-1+ . | BCL6−/ MUM1+/ syn-1− . | BCL6+/ MUM1+/ syn-1− . | |
| Systemic NHL | ||||
| BL (case 19) | 17 | 0 | 0 | 25-151 |
| DLCL (case 16) | 12 | 0 | 1 | 2 |
| IBL (case 12) | 0 | 7 | 5 | 0 |
| PCNSL | ||||
| DLCL (case 3) | 1 | 0 | 0 | 2 |
| IBL (case 12) | 0 | 7 | 3 | 0 |
| DLCL/IBL (case 7) | 2 | 1 | 0 | 1 |
| PBL (case 7) | 0 | 7 | 0 | 0 |
| PEL (case 105-152) | 0 | 10 | 0 | 0 |
| HL (case 16) | 0 | 15 | 0 | 0 |
| EBV+ | 14 of 32 | 38 of 47 | 8 of 9 | 4 of 7 |
| LMP1+ | 2 of 32 | 27 of 47 | 5 of 9 | 1 of 7 |
| . | Phenotypic patterns5-150 . | |||
|---|---|---|---|---|
| BCL6+/ MUM1−/ syn-1− . | BCL6−/ MUM1+/ syn-1+ . | BCL6−/ MUM1+/ syn-1− . | BCL6+/ MUM1+/ syn-1− . | |
| Systemic NHL | ||||
| BL (case 19) | 17 | 0 | 0 | 25-151 |
| DLCL (case 16) | 12 | 0 | 1 | 2 |
| IBL (case 12) | 0 | 7 | 5 | 0 |
| PCNSL | ||||
| DLCL (case 3) | 1 | 0 | 0 | 2 |
| IBL (case 12) | 0 | 7 | 3 | 0 |
| DLCL/IBL (case 7) | 2 | 1 | 0 | 1 |
| PBL (case 7) | 0 | 7 | 0 | 0 |
| PEL (case 105-152) | 0 | 10 | 0 | 0 |
| HL (case 16) | 0 | 15 | 0 | 0 |
| EBV+ | 14 of 32 | 38 of 47 | 8 of 9 | 4 of 7 |
| LMP1+ | 2 of 32 | 27 of 47 | 5 of 9 | 1 of 7 |
NHL indicates non-Hodgkin lymphoma; PCNSL, primary central nervous system lymphoma; see Table 1 for other abbreviations.
Other phenotypic patterns included: BCL6−/MUM1−/syn1− in 1 systemic NHL (with DLCL morphology) and in 1 PCNSL (with DLCL/IBL morphology); BCL6−/MUM1−/syn1+ in 2 PCNSL (with IBL morphology); BCL6+/MUM1+/syn1+ in 1 PCNSL (with DLCL/IBL morphology) and in 1 HL; and BCL6+/MUM1−/syn1+ in 1 PCNSL (with DLCL/IBL morphology).
In 2 cases occasional neoplastic cells expressed MUM1.
In 1 PEL case the expression of BCL-6 could not be assessed because the immunohistochemistry result was not evaluable for technical reasons.